ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
low e2 symptoms didnt go away after crash
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 119508" data-attributes="member: 13851"><p><strong>Clinical Use of Aromatase Inhibitors in Males</strong></p><p></p><p>AIs are classified as either type 1 (steroidal) or type 2 (nonsteroidal). Examples of steroidal AIs are testolactone, formestane, and exemestane, which inhibit aromatase activity by mimicking the substrate androstenedione. They irreversibly inhibit the aromatase enzyme by covalently binding to it; as such they are also known as “suicidal inhibitors.”</p><p></p><p>Nonsteroidal AIs inhibit enzyme activity by reversibly binding with the heme iron of the enzyme, resulting in competitive inhibition. Examples of nonsteroidal AIs are aminoglutethimide, fadrozole, anastrozol, letrozole, and vorozole (Table 1).</p><p></p><p>AIs are further classified into generations based on their efficacy. First generation inhibitors (e.g., aminoglutethimide) are relatively weak and nonspecific, whereas third generation AIs (e.g., letrozole and anastrozole) are most potent, most specific, and least toxic. Their pharmacokinetic properties (t1/2 of 48 hours for ansatrozole and letrozole and t1/2 of 27 hours for exemestane) allow for a once-daily dosing schedule. Their selective inhibitory properties negate the need for corticosteroidal or mineralocorticoid supplementation, which is essential for the nonspecific AI aminogluthimide. The second generation AIs are in between with regard to potency, specificity, and toxicity (e.g., formestane and fadrozole). <strong><span style="color: rgb(184, 49, 47)">Third generation AIs have been reported to have close to 100% inhibition of the enzyme, but this is not the case in males. In men, third-generation AIs will decrease the mean plasma estradiol/testosterone ratio by 77% [41,42]. </span></strong>This can be explained by the higher plasma concentration of testosterone in eugonal adult men compared with women. Because inhibition of aromatase is dose dependent, aromatase is less suppressed in the testis compared with adipose and muscle, thus explaining the incomplete efficacy of aromatase inhibition in males. The molar ratio of testosterone to AI and testicular aromatase activity is higher compared with adipose and muscle tissue. As mentioned earlier in this article, low estradiol levels are detrimental to bone health and sexual function. Thus, this incomplete suppression may be advantageous to men, and this lowers the risk of the potential side effects of AIs. Long-term use of potent AIs reduces circulating estradiol levels by 88% [43]. This is associated with adverse effects on bone [44,45] and could possibly be associated with increased body fat in men [22].</p></blockquote><p></p>
[QUOTE="madman, post: 119508, member: 13851"] [B]Clinical Use of Aromatase Inhibitors in Males[/B] AIs are classified as either type 1 (steroidal) or type 2 (nonsteroidal). Examples of steroidal AIs are testolactone, formestane, and exemestane, which inhibit aromatase activity by mimicking the substrate androstenedione. They irreversibly inhibit the aromatase enzyme by covalently binding to it; as such they are also known as “suicidal inhibitors.” Nonsteroidal AIs inhibit enzyme activity by reversibly binding with the heme iron of the enzyme, resulting in competitive inhibition. Examples of nonsteroidal AIs are aminoglutethimide, fadrozole, anastrozol, letrozole, and vorozole (Table 1). AIs are further classified into generations based on their efficacy. First generation inhibitors (e.g., aminoglutethimide) are relatively weak and nonspecific, whereas third generation AIs (e.g., letrozole and anastrozole) are most potent, most specific, and least toxic. Their pharmacokinetic properties (t1/2 of 48 hours for ansatrozole and letrozole and t1/2 of 27 hours for exemestane) allow for a once-daily dosing schedule. Their selective inhibitory properties negate the need for corticosteroidal or mineralocorticoid supplementation, which is essential for the nonspecific AI aminogluthimide. The second generation AIs are in between with regard to potency, specificity, and toxicity (e.g., formestane and fadrozole). [B][COLOR=rgb(184, 49, 47)]Third generation AIs have been reported to have close to 100% inhibition of the enzyme, but this is not the case in males. In men, third-generation AIs will decrease the mean plasma estradiol/testosterone ratio by 77% [41,42]. [/COLOR][/B]This can be explained by the higher plasma concentration of testosterone in eugonal adult men compared with women. Because inhibition of aromatase is dose dependent, aromatase is less suppressed in the testis compared with adipose and muscle, thus explaining the incomplete efficacy of aromatase inhibition in males. The molar ratio of testosterone to AI and testicular aromatase activity is higher compared with adipose and muscle tissue. As mentioned earlier in this article, low estradiol levels are detrimental to bone health and sexual function. Thus, this incomplete suppression may be advantageous to men, and this lowers the risk of the potential side effects of AIs. Long-term use of potent AIs reduces circulating estradiol levels by 88% [43]. This is associated with adverse effects on bone [44,45] and could possibly be associated with increased body fat in men [22]. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
low e2 symptoms didnt go away after crash
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top